
Pfizer (PFE) Stock Forecast & Price Target
Pfizer (PFE) Analyst Ratings
Bulls say
Pfizer is positioned for strong growth with its portfolio of top-selling products, global reach with a strong presence in emerging markets, and a robust pipeline with potential catalysts in the near future such as the MEVPRO-1 data and Litfulo Phase 3 data. There are potential risks, such as disappointing clinical data or regulatory setbacks in the pipeline and macroeconomic concerns, but the potential upside outweighs these risks, making Pfizer a strong investment opportunity with an expected 6% upside and limited downside.
Bears say
Pfizer is facing numerous challenges, including increasing competition and significant patent expirations in the coming years. In addition, their recent cost-cutting program and R&D cuts in infectious diseases raise questions about their sustainability initiatives and global health leadership. The company's limited diversity at the C-suite level and concerns over their COVID-19 vaccine pricing strategy also impact their strategic credibility. These factors, combined with their lower growth profile and higher exposure to LOEs, justify our negative outlook on the stock and our underperform rating and price target.
This aggregate rating is based on analysts' research of Pfizer and is not a guaranteed prediction by Public.com or investment advice.
Pfizer (PFE) Analyst Forecast & Price Prediction
Start investing in Pfizer (PFE)
Order type
Buy in
Order amount
Est. shares
0 shares